The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Patient-reported outcomes from the GRIFFIN trial: D-RVd versus RVd in multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses patient-reported outcomes from the GRIFFIN trial (NCT02874742), which investigated adding daratumumab to lenalidomide, bortezomib, and dexamethasone (D-RVd) in multiple myeloma. The trial found that D-RVd did not negatively impact quality of life (QoL) compared to RVd, and some measures even improved. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, GSK, Janssen, Takeda, Oncopeptides, Celgene/BMS, Karyopharm, Takeda.
